Current research status on immune-related adverse events
Immune checkpoint inhibitors have progressed rapidly over the past decade and have become one of the most promising oncology treatments. However, immune checkpoint inhibitors reduce T-cell tolerance and lead to a unique spectrum of immune-related adverse events (IRAE). IRAE can involve multiple systems, including endocrine, gastrointestinal, respiratory and skin systems and there is no predictive marker with high specificity and sensitivity. Mild IRAE can be alleviated by discontinuing immune checkpoint inhibitors while severe IRAEs require active intervention. The first-line treatment is glucocorticoids, and immunosuppressants can be considered in refractory cases. However the optimal choice of immunosuppressants is currently controversial. This review provides an overview of the epidemiology and possible mechanisms of immune-related adverse events, outlines some promising predictive biomarkers, and describes several immunotherapy-related organ toxicity and management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery - 25(2022), 3 vom: 25. März, Seite 271-276 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
|---|
| Links: |
|---|
| Themen: |
Cytotoxic T lymphocyte associated antigen-4 |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 01.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn441530-20220223-00058 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338703683 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338703683 | ||
| 003 | DE-627 | ||
| 005 | 20231226001249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn441530-20220223-00058 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338703683 | ||
| 035 | |a (NLM)35340178 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Hua, Y W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current research status on immune-related adverse events |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Immune checkpoint inhibitors have progressed rapidly over the past decade and have become one of the most promising oncology treatments. However, immune checkpoint inhibitors reduce T-cell tolerance and lead to a unique spectrum of immune-related adverse events (IRAE). IRAE can involve multiple systems, including endocrine, gastrointestinal, respiratory and skin systems and there is no predictive marker with high specificity and sensitivity. Mild IRAE can be alleviated by discontinuing immune checkpoint inhibitors while severe IRAEs require active intervention. The first-line treatment is glucocorticoids, and immunosuppressants can be considered in refractory cases. However the optimal choice of immunosuppressants is currently controversial. This review provides an overview of the epidemiology and possible mechanisms of immune-related adverse events, outlines some promising predictive biomarkers, and describes several immunotherapy-related organ toxicity and management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cytotoxic T lymphocyte associated antigen-4 | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Immune-related adverse events | |
| 650 | 4 | |a Programmed death-1 | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Zhao, L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery |d 2005 |g 25(2022), 3 vom: 25. März, Seite 271-276 |w (DE-627)NLM157648419 |x 1671-0274 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:3 |g day:25 |g month:03 |g pages:271-276 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn441530-20220223-00058 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 3 |b 25 |c 03 |h 271-276 | ||